All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Rheumatoid arthritis (RA) is an autoimmune condition with a predilection for peripheral synovial joints. Inadequate or poor control of inflammation results in chronic pain, joint destruction, and decreased functional ability. Osteoporosis and osteopenia are common in patients with RA, and a variety of factors predispose RA patients to rapid loss of bone, including pro-inflammatory cytokines that augment osteoclast activity, certain medications taken to treat the disease such as oral corticosteroids, and decreased mobility. Levels of mobility and functional ability have been shown to be related to bone mineral density (BMD), as have age, stature, and sex, independently of RA disease \[[@pone.0153470.ref001]\], \[[@pone.0153470.ref002]\].

Moderate and vigorous habitual physical activities have known osteogenic effects \[[@pone.0153470.ref003]\]. Conversely, increased time spent in sedentary behaviours has been independently associated with poor bone mass in healthy populations \[[@pone.0153470.ref004]\]. Patients with RA spend the majority of their day being sedentary \[[@pone.0153470.ref005]\]. Furthermore, a large qualitative study conducted in female patients with RA found that patients reported pain and decreased functional ability as having the most widespread effect on their daily lives \[[@pone.0153470.ref006]\]. Inability to perform normal daily activities not only decreases quality of life, but also further perpetuates a sedentary lifestyle. Functional ability as assessed by the Health Assessment Questionnaire (HAQ), has been shown to be improved following certain exercise interventions conducted in patients with RA \[[@pone.0153470.ref007]\], yet there is still no consensus on the most feasible type of exercise intervention for patients with chronic pain and, often severe disability.

The beneficial effects of both aerobic and resistance exercise interventions to the health of patients with RA has been proven \[[@pone.0153470.ref008]\], yet exercise interventions in RA are not always feasible, specifically bone loading exercises which need to be dynamic in order to increase bone mass \[[@pone.0153470.ref009]\]. Whole body vibration (WBV) is safe, and requires minimal effort and movement \[[@pone.0153470.ref010]\]. The vibratory waves generated by a mechanical vibration platform produce energy via forced oscillation, which is then transferred to an individual via propagation through the feet, legs, trunk and the head \[[@pone.0153470.ref011]\]. WBV therapy has been shown to decrease fatigue and pain levels, and to improve muscle strength in patients with fibromyalgia \[[@pone.0153470.ref012]\], \[[@pone.0153470.ref013]\], and to decrease pain levels in patients with knee osteoarthritis \[[@pone.0153470.ref010]\], as well as to increase strength and balance, in various chronic conditions \[[@pone.0153470.ref014]\]. Furthermore, studies conducted in postmenopausal women \[[@pone.0153470.ref015]\], as well as in younger healthy populations \[[@pone.0153470.ref016]\], and athletes with low BMD \[[@pone.0153470.ref017]\] have shown WBV therapy to improve BMD, particularly at the hip and spine \[[@pone.0153470.ref018]\], \[[@pone.0153470.ref019]\].

WBV therapy has not, to the best of our knowledge, been used as a form of exercise in patients with RA. Furthermore, of the studies that have used WBV therapy in other populations, none have examined whether WBV therapy induced effects are sustained post intervention. The primary aim of this study was to determine the effects of a WBV programme on functional ability in patients with established RA. Secondly, the study aimed to determine any effects WBV therapy may have on BMD, RA disease activity, indices of health related quality of life (HRQoL), physical activity profiles, and body composition.

Patients and Methods {#sec002}
====================

Study design {#sec003}
------------

In this longitudinal study, consenting female patients were assigned (using an alternating method) to either a WBV group who underwent the WBV therapy, or a control (CON) group who continued with their normal daily activities. Following a baseline assessment (assessment 1), patients underwent the relevant intervention (WBV therapy or normal activity) for a three month period, following which all patients returned for a follow up assessment (assessment 2) in order to determine the effects of the WBV therapy intervention in comparison to the CON group. Thereafter, all patients continued with their normal activities for a further three months, following which a three month post intervention assessment was conducted (assessment 3) in order to determine whether any WBV therapy effects were sustained. Patients were enrolled from April to August 2013, the first follow up was completed for all participants by November 2013, and the final follow up for all participants was completed by the end of February 2014. The full protocol for this study has been published elsewhere \[[@pone.0153470.ref020]\]. The study protocol and CONSORT checklist can be found in the supporting information: [S1 Text](#pone.0153470.s002){ref-type="supplementary-material"} and [S2 Text](#pone.0153470.s003){ref-type="supplementary-material"}. The trial registration information for this study is PACTR201405000823418 (19/05/2014) and is available as [S3 Text](#pone.0153470.s004){ref-type="supplementary-material"}. This trial was only registered after data collection commenced as the protocol was first piloted for feasibility before registration.

Patients {#sec004}
--------

Thirty nine adult female patients who met the 1987 American College of Rheumatology classification criteria \[[@pone.0153470.ref021]\], had established disease of at least three years duration, and were on stable drug therapy (prednisone \<10mg/day) for at least three months were included in the study. Patients were recruited and assessed at the Chris Hani Baragwanath Academic Hospital and gave written informed consent to be included in the study. Exclusion criteria were known HIV disease, use of bisphosphonates for the treatment of osteoporosis, any co-morbidities that could potentially impact on physical activity levels, use of assistive walking devices, previous hip or knee joint replacement surgery or arthroplasty, and pregnancy. Ethical approval was obtained from the Human Research Ethics Committee of the University of the Witwatersrand (M130113), and this trial conforms to the guidelines set out in the Declaration of Helsinki.

Whole body vibration therapy intervention {#sec005}
-----------------------------------------

Whole body vibration therapy consisted of two 15 minute session per week (total of 24 sessions over 12 weeks) of supervised therapy, which comprised of ten repetitions standing on the vibration plate for 60 seconds, followed by a 30 second rest period. This intermittent protocol was designed to increase osteogenic effects \[[@pone.0153470.ref022]\] and has previously been used successfully \[[@pone.0153470.ref017]\]. All WBV training was performed on the same vertical synchronous vibration plate (DKN XG 5.0, DKN Technology, California, USA). Different vibration platforms exist; vertical synchronous platforms move both legs up and down in unison, while oscillating plates move each leg up and down in a side-alternating manner. Vertical plates have most often been used to produce anabolic effects at the hip and spine as transmission of frequencies is site specific (vertical transmissions move in a vertical plane while side-alternating transmissions move in a more lateral plane); and accelerations produced are generally greatest at anatomical sites closest to the vibration platform \[[@pone.0153470.ref023]\]. Vibration was set at 3mm amplitude and a frequency of 30Hz in all instances, as lower amplitude, higher frequency vibrations have been shown to elicit greater responses in bone \[[@pone.0153470.ref024]\], and similar frequencies and amplitudes have been used in patients with fibromyalgia \[[@pone.0153470.ref014]\]. Patients were taught the correct posture (barefoot, holding on to the handle bars with knees slightly bent) while on the vibration plate in order to maximise the vibration effect while minimising any harmful effects, and to standardise procedure. All sessions were monitored by the primary investigator (AP) for compliance and accuracy. The CON group was instructed to continue with their normal daily activities for the three month period.

Outcome assessments {#sec006}
-------------------

### Functional ability assessment {#sec007}

All patients were assessed at each time period for functional ability using the modified Health Assessment Questionnaire (mHAQ). The mHAQ is a well validated, self-administered, RA specific questionnaire that assesses functional ability in eight domains of daily activities where scores range from 0 (no disability) to 3 (severe disability) \[[@pone.0153470.ref025]\].

### Disease activity and HRQoL measurements {#sec008}

All patients were assessed at each time point for rheumatoid disease activity using the Clinical Disease Activity Index (CDAI) by the same physician (MAM, who was blinded to the assignment of patients to either the WBV group or CON group). Patients were also asked to self assess their fatigue levels using a Lickert scale anchored at 0 (not tired at all) and 5 (the most tired I have ever felt), as well as their pain anchored at 0 (no pain) and 5 (unbearable pain).

### Physical activity {#sec009}

Patients were fitted with an Actical (Respironics Inc., Murrysville, PA, USA) accelerometer worn on a Velcro belt on the right hip for a one week period at baseline, as well as at assessments 2 and 3 for the assessment of habitual physical activity. Patients then returned the accelerometer to the clinic one week later. Patients were instructed to wear the accelerometer all day, and to remove the device only while sleeping, bathing or showering. Actical data were recorded in one minute epochs and data were reduced by removing full days of non-wear time as observed by a full day of zero activity counts. Sleep time was removed by direct observation of the data \[[@pone.0153470.ref026]\], and only the remaining data were considered as wear time. Three days of wear time with a minimum of 10 hours of wear time per day was required for inclusion in the analysis \[[@pone.0153470.ref027]\].

### Activity data {#sec010}

The Actical accelerometer records activity counts, which, based on the number of counts per epoch, are then classified by the inbuilt Actical software into thresholds of intensity; namely sedentary (0--100 counts), light activity (101--1485 counts), moderate activity (1486--5557 counts), and vigorous activity (≥5558 counts). Data were thus considered "active" data if a minute epoch had an activity count that was greater than 100 (i.e.: light to moderate/vigorous activity). Activity bouts were then calculated as the number of times per day that at least 10 consecutive minutes of "active data" were recorded \[[@pone.0153470.ref028]\]. The number of times that sedentary activity was "broken up" was calculated as the number of times per day that a sedentary minute epoch (\<101 counts) was followed by at least one active minute epoch (\>100 counts); and these data were thus considered as a break in sedentary time \[[@pone.0153470.ref029]\]. Data were reported as average activity counts per day; percentage of time spent in sedentary, light, moderate and vigorous activity thresholds; average number of activity bouts per day, as well as average number of sedentary breaks per day. Patients wore the same Actical at both visits in order to minimise inter-device variability.

### BMD assessment {#sec011}

At each time point, patients underwent a Dual X-Ray Absorptiometry (DXA) scan to assess BMD and body composition. All patients were assessed for site specific areal BMD at the left hip, lumbar spine (L1-L4), and whole body. A single DXA operator was used throughout the study and was blinded as to the assignment of the patients to the WBV or CON group. A single machine was used (Hologic QDR 4500A, Hologic, Boston, USA), and was routinely calibrated throughout the study, using a phantom spine that was scanned daily to determine coefficients of variation of the machine. The coefficient of variation during the course of the study for spine BMD was 0.31%.

### Body composition {#sec012}

At each time point, height (measured to the nearest mm using a stadiometer (Holtaine, UK)), and body mass (measured to the nearest 100g using a standard digital scale (Dismed, USA) were measured. From these measurements Body Mass Index (BMI) was calculated. Total lean and fat mass measurements were obtained from the body composition component of the whole body DXA scan. Skeletal muscle index (SMI) was calculated by adding appendicular lean mass (left and right- arm and leg- lean masses), and dividing by height squared \[[@pone.0153470.ref030]\].

Statistical analysis {#sec013}
--------------------

All analyses were conducted using Stata 12/IC 12.0 for Mac (StataCorp LP, College Station TX, USA) and p value of \< .05 was considered statistically significant. A two sided sample size calculation for means with repeated measures (ß = 0.10) showed that at a 5% level (using an SD of 0.19) a sample of 8 patients in each group would be required in order to detect a minimum clinically important difference of 0.22 in mHAQ score \[[@pone.0153470.ref031]\] with a power of 90%. Students unpaired t-tests were used to compare continuous variables between the WBV group and CON group at baseline. Thereafter, to assess the effect of the intervention on the primary and secondary outcomes, individual linear mixed models were used for each dependent variable. Random intercepts were used to account for within person correlation of repeated measures and missing data as per an intention to treat analysis. To test a priori hypothesis, the estimated mean scores at each time point (three- and six months post baseline) were contrasted with baseline values for main effects, and group by time interactions as well as 95% confidence intervals (CI) were calculated. Model fit was assessed using residual plots and diagnostics. Percentage change from baseline was calculated and compared between groups using Students unpaired t-tests. All continuous variables are expressed as means and standard deviations (SD) or means and standard error of the means (SEM).

Results {#sec014}
=======

Patient characteristics {#sec015}
-----------------------

Following enrollment, eight patients were excluded due to not being able to attend the required assessments. These patients were no different from completers in terms of age, disease duration, or functional ability (all p\>0.05). Hence, 31 patients were allocated to the WBV group (n = 16) or the CON group (n = 15) and completed the three month intervention, however at assessment 3, one patient in the WBV group and three patients in the CON group were lost to follow up due to no longer being interested in participating, or not being able to attend the required assessments ([Fig 1](#pone.0153470.g001){ref-type="fig"}). Data can be found in the supporting information: [S1 Data](#pone.0153470.s001){ref-type="supplementary-material"}.

![Number of study patients initially enrolled and followed up at each assessment time point.](pone.0153470.g001){#pone.0153470.g001}

At baseline, there were no differences between the WBV group and the CON group for any of the variables measured as shown in [Table 1](#pone.0153470.t001){ref-type="table"}. There were no differences between the WBV and CON groups for BMD at any of the sites measured at baseline (data shown in [Table 2](#pone.0153470.t002){ref-type="table"}). Furthermore, there were no differences between the WBV and CON groups for average physical activity levels (p = 0.63, data shown in [Table 2](#pone.0153470.t002){ref-type="table"}). Baseline (assessment 1), post intervention (assessment 2), and six month follow up (assessment 3) data for mHAQ, BMD, RA disease and physical activity variables are presented in [Table 2](#pone.0153470.t002){ref-type="table"}.

10.1371/journal.pone.0153470.t001

###### Patient characteristics at baseline in the WBV group and CON group.

Data are mean (SD).

![](pone.0153470.t001){#pone.0153470.t001g}

                             WBV (n = 16)   CON (n = 15)   p value
  -------------------------- -------------- -------------- ---------
  Age (years)                51(10)         52(12)         0.81
  Disease duration (years)   10(11)         12(8)          0.54
  Height (m)                 1.59(0.07)     1.55(0.08)     0.16
  Body mass (kg)             85.24(21.96)   80.76(23.63)   0.59
  CDAI                       11(9)          8(6)           0.33
  mHAQ (max. of 3)           1.22(0.67)     1.13(0.86)     0.74
  Pain (max. of 5)           4(3)           4(3)           0.92
  Fatigue (max. of 5)        4(3)           3(3)           0.35
  Lean body mass (kg)        45.65(8.48)    42.11(7.96)    0.25
  \% body fat                42(7)          41(6)          0.55

CDAI--clinical disease activity index, mHAQ--modified health assessment questionnaire.

10.1371/journal.pone.0153470.t002

###### Mixed model analysis between the WBV and CON groups at baseline, three- and six month assessments.

Data are mean (SEM).

![](pone.0153470.t002){#pone.0153470.t002g}

                                                                    WBV           CON                                               Mixed models analysis (p value)                                                                                                                                                   
  -------------------------------- -------------------------------- ------------- ------------------------------------------------- ------------------------------------------------- ------------ ------------------------------------------------ ------------------------------------------------- ------ -------- --------
  **Functional Ability**           mHAQ (max. of 3)                 1.22(0.19)    1.02(0.19)                                        0.92(0.19)[\*](#t002fn003){ref-type="table-fn"}   1.13(0.20)   1.06(0.20)                                       1.17(0.20)                                        0.79   0.25     0.18
  **HRQoL and Disease activity**   Fatigue (/5)                     4.4(0.63)     1.1(0.65)[\*](#t002fn003){ref-type="table-fn"}    3.7(0.67)                                         3.4(0.67)    3.7(0.75)                                        3.7(0.72)                                         0.40   0.04     0.01
                                   Pain (/5)                        3.90(0.69)    3.07(0.71)                                        4.75(0.71)                                        4.00(0.71)   4.83(0.71)                                       4.75(0.78)                                        0.40   0.34     0.26
                                   CDAI                             11.10(1.88)   9.59(1.88)                                        9.64(1.94)                                        8.20(1.94)   10.33(1.94)                                      8.80(1.94)                                        0.59   0.91     0.56
  **Physical activity**            Average AC (/day)                7296(828)     7424(864)                                         7194(884)                                         6984(855)    6613(855)                                        6385(971)                                         0.53   0.85     0.88
                                   Sedentary (%/day)                68(2.6)       68(2.8)                                           70(2.8)                                           69(2.7)      70(2.8)                                          71(3.2)                                           0.67   0.57     0.96
                                   Light(%/day)                     21(1.70)      21(1.80)                                          19(1.85)                                          20(1.75)     20(1.75)                                         20(2.08)                                          0.80   0.65     0.92
                                   Moderate (%/day)                 11(1.27)      11(1.32)                                          10(1.35)                                          11(1.31)     10(1.31)                                         9(1.47)                                           0.59   0.50     0.91
                                   Vigorous (%/day)                 0.02(0.01)    0.02(0.01)                                        0.01(0.01)                                        0.01(0.01)   0.01(0.01)                                       0.00(0.01)                                        0.31   0.75     0.91
                                   Breaks sedentary time (\#/day)   61(3.3)       63(3.5)                                           63(3.6)                                           67(3.4)      60(3.4)[\*](#t002fn003){ref-type="table-fn"}     61(4.0)                                           0.90   0.59     0.14
                                   Activity bouts (\#/day)          3.1(0.59)     3.4(0.60)                                         3.0(0.61)                                         2.8(0.61)    2.1(0.61)[\*](#t002fn003){ref-type="table-fn"}   1.8(0.64)[\*](#t002fn003){ref-type="table-fn"}    0.26   0.14     0.16
  **Bone**                         Hip BMD (g.cm^2^)                1.01(0.05)    0.96(0.05)                                        0.94(0.05)                                        0.97(0.05)   0.94(0.05)                                       0.84(0.05)[\*](#t002fn003){ref-type="table-fn"}   0.37   0.01     0.50
                                   Spine BMD (g.cm^2^)              0.92(0.04)    0.92(0.04)                                        0.92(0.04)                                        0.91(0.04)   0.91(0.04)                                       0.91(0.04)                                        0.87   0.84     0.74
                                   Whole Body BMD (g.cm^2^)         1.09(0.03)    1.10(0.03)[\^](#t002fn004){ref-type="table-fn"}   1.10(0.03)[\*](#t002fn003){ref-type="table-fn"}   1.07(0.03)   1.07(0.03)                                       1.05(0.03)[\*](#t002fn003){ref-type="table-fn"}   0.47   0.15     \<0.01
  **Body Composition**             BMI (kg/m^2^)                    34(2.1)       34(2.1)                                           33(2.1)[\*](#t002fn003){ref-type="table-fn"}      34(2.2)      34(2.2)                                          34(2.2)                                           0.84   0.58     0.05
                                   Fat mass (kg)                    37(3)         36(3)                                             35(3)[\*](#t002fn003){ref-type="table-fn"}        31(3)        32(3)                                            35(3)[\*](#t002fn003){ref-type="table-fn"}        0.43   0.44     \<0.01
                                   Lean mass (kg)                   46(2)         46(2)                                             45(2)                                             42(2)        42(2)                                            40(2)[\*](#t002fn003){ref-type="table-fn"}        0.13   \<0.01   \<0.01
                                   SMI                              7.8(0.39)     8.0(0.39)[\^](#t002fn004){ref-type="table-fn"}    8.0(0.39)[\^](#t002fn004){ref-type="table-fn"}    7.7(0.40)    7.9(0.40)[\*](#t002fn003){ref-type="table-fn"}   7.4(0.41)[\*](#t002fn003){ref-type="table-fn"}    0.64   0.02     \<0.01

Breaks in sedentary time are adjusted for % total sedentary time at each time point.

mHAQ--modified health assessment questionnaire, HRQoL--health related quality of life, CDAI--clinical disease activity index, AC--activity counts, BMD--bone mineral density, BMI---body mass index, SMI--skeletal mass index.

\* Main effects significantly different from baseline after posthoc analysis (p\<0.05).

\^ Main effects showed trend towards significant difference from baseline after posthoc analysis (p\<0.07).

Functional ability {#sec016}
------------------

In the WBV group, mHAQ (where a lower score indicates an improved outcome) was improved (p = 0.02, CI -0.55 to -0.05) at assessment 3 as compared to baseline, while no changes were observed in the CON group at either assessment 2 or 3. [Fig 2](#pone.0153470.g002){ref-type="fig"} shows the mean change in mHAQ between the two groups from baseline at each assessment. Of patients who underwent WBV therapy, 63% showed an improvement in mHAQ, while 60% of patients in the CON group showed a worsened mHAQ score over the three month intervention period.

![Change in functional ability.\
Assessed by the modified Health Assessment Questionnaire (mHAQ) from baseline to post intervention (three month assessment) and six month follow up between the whole body vibration group (WBV) and the control group (CON).](pone.0153470.g002){#pone.0153470.g002}

HRQoL and disease activity {#sec017}
--------------------------

[Table 2](#pone.0153470.t002){ref-type="table"} shows the time effect (p = 0.04), as well as a group by time interaction (p = 0.01) for fatigue levels, where fatigue was decreased (p\<0.01, CI -4.82 to -1.67) in the WBV group at assessment 2 as compared to baseline, however this effect was not sustained at assessment 3. No changes were observed in the CON group for fatigue levels over the study period. [Fig 3](#pone.0153470.g003){ref-type="fig"} shows the percentage change in fatigue scores for each individual at the post intervention assessment as compared to baseline. Percentage change showed a trend towards being significantly greater in the WBV group compared to the CON group (p = 0.06). There were no changes in CDAI scores over the intervention period for either of the groups. There were no changes in pain levels over the study period for either of the groups.

![Percentage change in fatigue.\
From baseline to post intervention (three month assessment) for each participant in the whole body vibration group (WBV) and the control group (CON) where a negative change indicates less fatigue. Percentage change was greater in the WBV group (p = 0.06).](pone.0153470.g003){#pone.0153470.g003}

Physical activity {#sec018}
-----------------

No main effects, or group by time interactions were observed for physical activity levels ([Table 2](#pone.0153470.t002){ref-type="table"}). No changes were evident in either group for average activity counts per day, or percentage of time spent in sedentary, light, moderate or vigorous activity over the study period. However, in the CON group, there were fewer breaks in sedentary time (after adjusting for percentage of time in sedentary activity at each time point) (p = 0.05) at assessment 2 as compared to baseline. In the CON group, there was also a decrease (p = 0.05, CI -1.79 to -0.16) in number of activity bouts per day at assessment 2 as compared to baseline; and this effect was sustained at assessment 3 compared to baseline assessment (p = 0.01). No changes were observed in the WBV group for number of breaks in sedentary time, or number of active bouts.

Bone mineral density {#sec019}
--------------------

Hip BMD was lower (p = 0.01, CI -0.23 to -0.03) in the CON group at assessment 3 compared to baseline. No changes were observed for the WBV group. There were no changes in spine BMD over the study period for either of the groups. A time and group interaction was evident for whole body BMD (p\<0.01), whereby there was a trend towards a significant (p = 0.06) increase in whole body BMD for the WBV group at assessment 2, and BMD was further increased at assessment 3 compared to baseline (p = 0.05, CI -0.01 to 0.01) ([Table 2](#pone.0153470.t002){ref-type="table"}). In the CON group, whole body BMD was decreased (p\<0.01, CI -0.02 to -0.002) at assessment 3 compared to baseline. When comparing the two groups at assessment 3, the WBV group showed improvement in whole body BMD by an average of (0.90(0.53)%) compared to the CON group, who on average lost 0.66(0.52)%, p = 0.04). [Fig 4](#pone.0153470.g004){ref-type="fig"} shows percentage change in whole body BMD at six months compared to baseline for each participant. The WBV group showed sustained improvements, while the CON group showed sustained losses in whole body BMD (p\<0.001).

![Percentage change in whole body bone mineral density.\
From baseline to six month follow up for each participant in the whole body vibration group (WBV) and the control group (CON) where a positive change indicates improved BMD. Percentage change was greater in the WBV group (p\<0.001).](pone.0153470.g004){#pone.0153470.g004}

Body composition {#sec020}
----------------

[Table 2](#pone.0153470.t002){ref-type="table"} shows the group by time interaction effects for BMI (p = 0.05) and fat mass (p\<0.01), both were decreased in the WBV group at assessment 3 as compared to baseline (p = 0.02, CI -1.20 to -0.08 and p = 0.01, CI -3794.93 to -416.50 respectively). In the CON group, fat mass increased (p\<0.01, CI 1637.79 to 5830.64) at assessment 3 compared to baseline. Lean mass and SMI showed time effects (p\<0.01, and p = 0.02 respectively), as well as group by time interactions (both p\<0.01). Lean mass was decreased (p\<0.01, CI -3363.64 to -1167.29) in the CON group at assessment 3 as compared to baseline. SMI showed a trend towards significant increase (p = 0.06) in the WBV group at assessment 2 from baseline, which was sustained at assessment 3 from baseline (p = 0.08), while in the CON group SMI was decreased (p\<0.01, CI -1508.21 to -205.49) at assessment 2 from baseline, and at assessment 3 from baseline (p = 0.02, CI -1790.77 to -488.05).

Discussion {#sec021}
==========

The three month WBV therapy intervention in patients with RA had positive effects on functional ability, HRQoL, physical activity profiles, BMD and body composition. Importantly, mHAQ scores started to improve in patients who underwent the three month WBV therapy intervention, and were significantly improved at the six month follow up. Also of importance is the maintenance of whole body BMD observed in the WBV group after cessation of WBV therapy, as well as the attenuation of loss of hip BMD in the WBV group in comparison to the losses of hip BMD observed in the control group. The findings presented in the current lend support to the possibility that WBV therapy may be useful for increasing functional ability, as well as having a protective effect of bone health in patients with RA.

Improvements in activities of daily living as assessed by the mHAQ, is one of the key outcome measures of RA treatment \[[@pone.0153470.ref032]\]. The majority of patients (63%) who underwent WBV therapy showed either no change, or improvements in mHAQ scores. The overall improvement in mHAQ scores following the passive exercise programme used in the present study is comparable with those observed following active exercise interventions in groups of people with RA, which utilised either strength training \[[@pone.0153470.ref033]\], \[[@pone.0153470.ref034]\], or aerobic exercise programmes \[[@pone.0153470.ref035]\]. A WBV therapy intervention could therefore be a feasible means to improve the ability of these patients to perform their normal daily activities, thereby greatly increasing their sense of well being. WBV therapy has been shown to improve anti-inflammatory status in an elderly population \[[@pone.0153470.ref036]\], which may impact patient's ability to function normally. Improvements in functional ability may also provide some protective effect on bone health in patients with RA, by allowing patients to be more mobile and thus potentially less sedentary.

Fatigue and 'feeling well' are important and relevant outcomes from the patient perspective in RA, and two of the most relevant improvements to note following treatment interventions in RA \[[@pone.0153470.ref032]\], \[[@pone.0153470.ref037]\]. Despite RA disease activity remaining unchanged following the WBV therapy intervention, fatigue levels were significantly improved by 53% (however these effects were not maintained at the six month follow up). The positive effects of WBV therapy on fatigue are similar to those observed in a cohort of patients with fibromyalgia who underwent a 6 week mixed WBV and exercise intervention where decreases in fatigue levels, as well as pain levels were observed, compared to a group that underwent exercise alone, and a control group where no changes were observed \[[@pone.0153470.ref012]\]. Another study conducted in patients with osteoarthritis also used a mixed exercise and WBV programme and were able to elicit improvements in pain levels over 8 weeks \[[@pone.0153470.ref010]\]. Moreover, WBV therapy in the present study has shown similar effects on well being as have aerobic and resistance exercise interventions in RA in previous studies \[[@pone.0153470.ref007]\], \[[@pone.0153470.ref035]\], \[[@pone.0153470.ref038]\].

Previous research has shown that higher levels of habitual physical activity in patients with RA are correlated with improved fatigue levels, as well as functional ability \[[@pone.0153470.ref005]\]. Recent literature has focused on the beneficial effects of breaking up sedentary time on health, regardless of overall activity levels \[[@pone.0153470.ref039]\], as well as the beneficial effects of being more active (often requiring activity to be performed in 10 minute bouts) \[[@pone.0153470.ref040]\]. Although overall physical activity remained unchanged before and after the intervention for both groups, there were important changes observed in the patterns of physical activity that should be considered. The CON group decreased the number of times they broke up their sedentary time and also had fewer bouts of activity following the intervention signifying more time spent in prolonged period of uninterrupted sedentary time in this group, yet activity profiles were maintained in the WBV group throughout the intervention period. Limiting sedentary time has been shown to have beneficial effects on bone health \[[@pone.0153470.ref004]\]. It is possible that the WBV therapy intervention, by means of decreasing fatigue levels, allowed patients to modify their habitual physical activity profiles and to start engaging in less sedentary behaviours, thereby becoming more functional.

In an RA population, where bone health is often compromised and increasing the risk of fractures, maintenance of BMD is an important secondary goal of treatment. In the present study it was found that WBV therapy improved whole body BMD in most patients (non significant average 8% increase from baseline), and that this effect was carried forward for a further three months (significant average 9% increase from baseline). WBV therapy also preserved hip BMD levels, while the CON group experienced losses in BMD at both the hip (-13%) and whole body (-1%) over the six month period. The loss of hip BMD in the CON group was greater than the least significant change needed for clinical relevance of 0.02g.cm^2^ at the hip (0.04g.cm^2^ is needed at the spine \[[@pone.0153470.ref041]\]). As expected in a group of women with RA, the WBV group also experienced clinically relevant decreases in hip BMD, yet these were much smaller and non significant. Healthy participants of a similar age range have been shown to lose 3% BMD at the hip over one year \[[@pone.0153470.ref042]\], and the NHANES database values for healthy women between 40--50 years shows approximately 5% decrease over 10 years \[[@pone.0153470.ref043]\]. Hip BMD has been shown to be the best predictor of fracture risk at any site \[[@pone.0153470.ref044]\], and WBV therapy may thus be considered as an adjunct therapeutic option for counteracting the very rapid loss of BMD that occurs in women with RA.

We, and others, have previously shown that WBV therapy improves or maintains BMD to varying degrees, particularly at the hip and spine. Versheuren et al in 2004 \[[@pone.0153470.ref019]\] and Rubin et al in 2004 \[[@pone.0153470.ref018]\] showed that WBV training for a six month and a one year period respectively, was able to significantly increase hip BMD by up to 0.93% (and 1.37% in only compliant participants) in a group of postmenopausal women. Rubin and colleagues further showed improvements in spine BMD of 0.49% in the compliant subset of their cohort. Prioreschi et al in 2012 were also able to show increases in hip BMD of 1.65%, and attenuated losses of spine BMD in a group of road cyclists who participated in only 10 weeks of intermittent WBV therapy \[[@pone.0153470.ref017]\]. Some studies have found no effects of WBV therapy on bone \[[@pone.0153470.ref023]\], however confounding variables such as Vitamin D and calcium supplementation in the control group, young age of participants, use of oscillating platforms, and lack of an intermittent protocol could explain the lack of osteogenic effects observed in these studies. Site specific differences in BMD changes evident between studies may also be due to transmission of frequencies along differing axes due to the type of vibration plate used, and the amount of acceleration produced dependant on frequency and amplitude settings. WBV therapy was well tolerated by the present cohort, and could potentially be a feasible intervention for BMD in patients with RA that does not require the vigorous, high-impact movements that are usually required to increase BMD (yet are often not feasible in this population). Although the exact mechanisms whereby WBV increases BMD remain unclear and depend on the frequencies and amplitudes utilised, it is likely that there are multiple mechanisms at play. Whole body vibration has been shown to activate fluid flow in the caniliculi and lacunae of bone matrix in rats \[[@pone.0153470.ref045]\], in a manner proportional to loading frequency, creating a shear stress on the plasma membrane of osteocytes, bone lining cells, and osteoblasts, which may respond accordingly \[[@pone.0153470.ref009]\]. However, Uzer et al., (2013) showed that *in vitro* fluid shear did not regulate vibration induced proliferation, and that cytoskeletal actin remodeling may play a greater role \[[@pone.0153470.ref046]\]. WBV activates mechanotransduction in bone and can stimulate osteogenesis \[[@pone.0153470.ref045]\], and low magnitude, high frequency vibration has been shown *in vitro* to upregulate osteoblast differentiation, matrix synthesis and mineralization, while regulating osteoclastic activity \[[@pone.0153470.ref024]\]. Furthermore, muscle forces exert osteogenic stimulus on bone, and the generation of these forces through vibration stimulus is a likely contributor to the skeletal adaptations that occur \[[@pone.0153470.ref047]\].

Although the frequency used in this study was chosen to achieve osteogenic effects, WBV therapy in this study also had a positive impact on body composition, lending support to the use of frequencies of 30Hz for affecting body composition. The WBV group in this study lost a significant amount of body mass (specifically -5% body fat) during the intervention period, maintained their lean muscle mass, and showed a trend towards improving SMI (an indicator of sarcopenia), while both SMI and lean mass were decreased in the CON group by 5% and 4% respectively. Sarcopenia, in combination with osteoporosis, greatly increases the risk of obtaining a fracture \[[@pone.0153470.ref048]\]. Whole body vibration has previously been shown to decrease BMI, and body fat (as measured by DXA) in obese women \[[@pone.0153470.ref049]\], to improve muscle strength in women with fibromyalgia \[[@pone.0153470.ref015]\], and to slow fat acquisition in rodent models \[[@pone.0153470.ref050]\]. This may be related to the ability of WBV therapy to increase oxygen consumption, energy expenditure, and neuromuscular performance \[[@pone.0153470.ref051]\] through continuously effecting eccentric and concentric muscular contractions \[[@pone.0153470.ref049]\], however higher frequencies are usually needed to elicit these effects. It is possible that the relatively low levels of habitual activity in this cohort allowed for changes in energy expenditure and thus body composition, even with lower frequencies of vibration. Alternatively, the simple participation in an organised activity twice weekly may have result in greater energy expenditure than normal. In both of the aforementioned studies a decrease in fat mass following WBV was mirrored by an increase in BMD or bone mineral content, which was not observed in the relevant control group. Although lower body mass is a known risk factor for low bone mass \[[@pone.0153470.ref052]\], and it is therefore assumed that higher body mass is protective of BMD, recent studies have suggested that obesity may have an inverse relationship with BMD \[[@pone.0153470.ref053]\], and that fractures that occur in obese populations should be considered 'fragility fractures' \[[@pone.0153470.ref054]\]. Potentially, obesity is distinct from 'high body mass' in terms of the effect it has on bone health; and should still be avoided in patients with RA, as is recommended in the general population. These results suggest that WBV therapy may be useful in decreasing body mass, as well as increasing lean muscle mass in patients with RA.

This study has strengths and limitations. The results showed that many of the benefits of WBV therapy in patients with RA can be sustained for at least three months post therapy. Furthermore, attrition rates were low, suggesting that the WBV program was well tolerated within this population. Unfortunately no qualitative assessments of the intervention were made, and thus the possibility that group participation had an effect on various outcomes cannot be negated. Since the intervention ran over a year period with staggered recruitment, the effects of the colder temperatures in winter may have altered various pain and well-being outcomes; however patients were recruited in an alternating manner, which would limit the potential differences between groups. Vitamin D, calcium intake and menopausal status were unfortunately not controlled for, which may have confounded changes in bone density. Furthermore, the small sample size and limited duration of the intervention must be considered.

In conclusion, the findings of this study show that a WBV therapy intervention can illicit sustained improvements in functional ability in females with RA. Bone mass at the hip and whole body was preserved, as was lean muscle mass. Patients who participated in the WBV therapy intervention also had improved fatigue levels without any changes in RA disease activity being observed. Furthermore, patients in the WBV group maintained their habitual physical activity profiles throughout the assessment period. Based on these findings, it seems that WBV therapy offers a useful and affordable adjunct therapy with sustained effects for patients with established RA, which does not require vigorous, high-impact movements. Future studies including qualitative assessments need to be conducted over a longer duration in a larger cohort of both males and females.
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